4 recruiting, 3 completed, 1 active not recruiting, 1 unknown. 6 Phase 3, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow K-115: new trials by email Literature Review of K-115 trials Research Report on K-115
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery Ripasudil, Placebo - Fuchs' Endothelial Dystrophy, Cataract | Phase 3 | Recruiting | Singapore Eye Research Institute | 120 | 2025-03-01 | 2025-01-29 |
| A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Ripasudil, Placebo - Fuchs Endothelial Corneal Dystrophy | Phase 3 | Completed | Kowa Research Institute, Inc. | 110 | 2023-05-11 | 2026-01-22 |
| A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Ripasudil, Placebo - Fuchs Endothelial Corneal Dystrophy | Phase 3 | Completed | Kowa Research Institute, Inc. | 107 | 2023-03-30 | 2026-05-27 |
| Descemet Endothelial Thickness Comparison Trial II Ripasudil, Placebo - Fuchs, Fuchs Dystrophy | Phase 3 | Recruiting | Stanford University | 60 | 2023-01-23 | 2026-08-17 |
| Study to Assess Safety and Tolerability of Multiple Doses of EO2002 EO2002, Ripasudil - Corneal Edema, Corneal Endothelial Dystrophy | Phase 1 | Recruiting | Asociación para Evitar la Ceguera en México | 12 | 2022-11-08 | 2025-12-08 |
| A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery Ripasudil, Placebo - Corneal Edema After Cataract Surgery | Phase 3 | Completed | Kowa Research Institute, Inc. | 330 | 2022-08-04 | 2026-09-02 |
| Descemet Endothelial Thickness Comparison Trial I Topical Ripasudil, Topical Placebo - Fuchs | Phase 3 | Active not recruiting | Stanford University | 160 | 2022-07-15 | 2026-08-17 |
| Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty - Fuchs Endothelial Dystrophy | Phase 2 | Unknown | Michael D. Straiko, MD | 72 | 2019-03-25 | 2024-03-20 |
| Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy Ripasudil hydrochloride hydrate 0.4% ophthalmic solution - Fuchs' Endothelial Dystrophy | Phase 4 | Recruiting | Marian Macsai, MD | 30 | 2017-12-06 | 2021-08-11 |
Fuchs' Endothelial Dystrophy (7) · Cataract (1) · Corneal Dystrophy, Posterior Polymorphous, 1 (1) · Corneal Edema (1)
Kowa Research Institute, Inc. (3) · Stanford University (2) · Asociación para Evitar la Ceguera en México (1) · Marian Macsai, MD (1) · Michael D. Straiko, MD (1) · Singapore Eye Research Institute (1)
United States (7) · Canada (2) · Denmark (2) · Germany (2) · Spain (2) · United Kingdom (2) · Mexico (1) · Puerto Rico (1) · Singapore (1)
Shona Pendse, MD, MMSc (3) · Jennifer Rose-Nussbaumer, MD (2) · Marcus Ang (1) · Michael D Straiko, M.D. (1) · Valeria Sanchez Huerta, MD (1)